System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 4 citations

PubMed: 40410203 DOI: 10.1038/s41514-025-00231-2

A 50-year journey in the development of treatment for benign prostatic hyperplasia.

NPJ Aging 11(1):41

Authors: Andrew V Schally, George Theodoropoulos, Wei Sha, Irving Vidaurre, Medhi Wangpaichitr

Affiliations

  • Endocrine and Polypeptide Institute, Veterans Affairs Healthcare System, Miami, FL, USA. Department of Veterans Affairs, Miami VA Healthcare System, Research Service, Miami, FL, USA. South Florida VA Foundation for Research and Education, Veterans Affairs Healthcare System, Miami, FL, USA. Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA. Department of Medicine, Divisions of Oncology and Endocrinology, University of Miami Miller School of Medicine, Miami, FL, USA. Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Department of Veterans Affairs, Miami VA Healthcare System, Research Service, Miami, FL, USA.
  • South Florida VA Foundation for Research and Education, Veterans Affairs Healthcare System, Miami, FL, USA.
  • Endocrine and Polypeptide Institute, Veterans Affairs Healthcare System, Miami, FL, USA.
  • Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Endocrine and Polypeptide Institute, Veterans Affairs Healthcare System, Miami, FL, USA. Department of Veterans Affairs, Miami VA Healthcare System, Research Service, Miami, FL, USA.
  • Endocrine and Polypeptide Institute, Veterans Affairs Healthcare System, Miami, FL, USA.
  • Department of Veterans Affairs, Miami VA Healthcare System, Research Service, Miami, FL, USA.
  • South Florida VA Foundation for Research and Education, Veterans Affairs Healthcare System, Miami, FL, USA.
  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Department of Surgery, Division of Thoracic Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.

Abstract

Recent research underscores the crucial role of hormone regulation in benign prostatic hyperplasia (BPH) and the therapeutic promise of growth hormone-releasing hormone (GH-RH) antagonists. BPH incidence in aging men doubled over three decades, driven by prostatic enlargement and lower urinary tract symptoms (LUTS). Aging-related changes in GH-RH and luteinizing hormone-releasing hormone (LH-RH) biology promote BPH through hormonal and inflammatory processes. Traditional therapies provide symptomatic relief but often fail to prevent progression. This review explores the 50-year extensive development of LH-RH and GH-RH peptide analogs from discovery to delivery and their potential in BPH treatment. In preclinical studies, GH-RH antagonists reduced prostate volume, improved LUTS, and modulated inflammation mediated by NF-κB and IGF-I. Clinical trials are needed to validate antagonist efficacy and safety. Given BPH's public health impact among the aged, and especially among aging Veterans, integrating GH-RH antagonists into management strategies may offer precision-based therapeutic advancements.

MeSH

Gonadotropin-Releasing Hormone, Aging, Hormones, Prostatic Hyperplasia, Therapeutics, Hyperplasia

Cited by